H.R. 3010 would prohibit pharmaceutical companies from deducting advertising expenses on their taxes when they directly advertise prescription drugs to the general public. The bill targets "direct-to-consumer advertising" through traditional media like television, radio, and billboards, as well as digital platforms such as social media and mobile apps, but excludes advertisements in medical journals. The restrictions apply to prescription drug manufacturers and compounding facility owners, effectively making such advertising more expensive by eliminating the tax break companies currently receive. The legislation would take effect immediately upon enactment and apply to advertising costs paid or incurred after the bill becomes law. Supporters contend this measure reduces taxpayer subsidies for drug marketing while critics may argue it could limit patient awareness of available treatments.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.